This inventor holds 2 USPTO granted patents and 3 published patent applications. Top assignee: Novartis Ag. Active years: 2023-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023-2024
Title: Spotlight on Inventor David Andrew Sandham
Introduction
David Andrew Sandham, based in Concord, MA, is an accomplished inventor with a focus on pharmaceutical innovations. He has made significant contributions to the field, holding a total of two patents that showcase his expertise and creativity in drug development.
Latest Patents
Sandham's latest patents include groundbreaking work on Heteroaryl substituted spiropiperidinyl derivatives and their pharmaceutical applications. The key invention provides a compound of a specific formula, or a pharmaceutically acceptable salt thereof, with defined characteristics that facilitate the method for manufacturing these compounds. Furthermore, these patents also detail their therapeutic uses, offering a combination of pharmacologically active agents and a comprehensive pharmaceutical composition.
Career Highlights
David Andrew Sandham is associated with Novartis AG, a leading company in the healthcare sector known for its innovation and commitment to improving patient outcomes. His work within this esteemed organization has allowed him to develop vital pharmaceutical solutions that contribute to advancements in healthcare.
Collaborations
Throughout his career, Sandham has collaborated with notable professionals such as Mallesh Bushaboina and Xin Chen. These collaborations not only enhance the depth of his research but also enable the fusion of diverse expertise that drives innovation in pharmaceutical development.
Conclusion
David Andrew Sandham exemplifies the spirit of innovation in the pharmaceutical industry. With his valuable patents and collaborative endeavors, he firmly establishes himself as a vital contributor to the development of novel therapeutic agents. His work continues to pave the way for advancements that may greatly benefit patients in need of effective treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
